# US 2019/0315849 A1 · Method of treating or preventing stroke

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315849 A1
- Document ID: US20190315849A1
- Status: Published application
- Kind: A1
- Application number: 16/411,321
- Filed: 2019-05-14
- Published: 2019-10-17
- Earliest claimed: 2014-11-17
- Assignees: CSL Limited; B-Creative Sweden AB
- Applicants: CSL Limited; B-Creative Sweden AB
- Inventors: Ulf ERIKSSON; Ingrid NILSSON; Daniel LAWRENCE; Enming Joe SU
- Web page: https://patentgrep.com/patent/US20190315849A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 38/482: {Serine endopeptidases (3.4.21)}
- A61K 38/4886: {Metalloendopeptidases (3.4.24), e.g. collagenase}
- A61K 38/49: Urokinase; Tissue plasminogen activator
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- C12Y 304/21068: Tissue plasminogen activator (3.4.21.68), i.e. tPA
- C12Y 304/21073: u-Plasminogen activator (3.4.21.73), i.e. urokinase
- C12Y 304/24029: Aureolysin (3.4.24.29)
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

A method of reducing an effect of stroke in a subject, the method comprising administering to the subject a compound that inhibits VEGF-B signaling.

## Claims

### Claim 1

A method of reducing an effect of stroke in a subject, the method comprising administering to the subject a compound that inhibits VEGF-B signaling.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound that inhibits VEGF-B signaling is administered before or after the stroke.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject suffers from diabetes and/or obesity.

### Claim 4 (depends on 3)

The method of claim 3, wherein the diabetes is type 2 diabetes.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject has one or more of the following characteristics:
has already suffered from a stroke and/or a transient ischemic attack;
has a family history of stroke;
suffers from heart disease;
has high blood pressure;
has high plasma low density lipoprotein levels;
has metabolic syndrome
has a cardiac abnormality;
has undergone cardiac surgery or hip replacement surgery.

### Claim 6 (depends on 2)

The method of claim 2, wherein the compound is administered after the stroke and the method comprises administering a combination of the compound that inhibits VEGF-B signaling and a thrombolytic compound.

### Claim 7 (depends on 6)

The method of claim 6, wherein the compound that inhibits VEGF-B signaling is administered before the thrombolytic compound.

### Claim 8 (depends on 7)

The method of claim 7, wherein administration of the compound that inhibits VEGF-B signaling extends the time in which the thrombolytic compound can safely be administered to the subject.

### Claim 9 (depends on 6)

The method of claim 6, wherein the thrombolytic compound is administered more than two hours after onset of symptoms of a stroke, or between two and six hours after onset of symptoms of a stroke.

### Claim 10 (depends on 6)

The method of claim 6, wherein the subject has blood glucose levels greater than 400 mg/dL.

### Claim 11 (depends on 6)

The method of claim 6, wherein the thrombolytic compound is selected from the group consisting of a tissue plasminogen activator, lanetoplase, reteplase, staphylokinase, streptokinase, anistreplase, desmoteplase or an urokinase.

### Claim 12 (depends on 1)

The method of claim 1, wherein the compound(s) is(are) administered in an amount sufficient to have one or more of the following effects:
reducing infarct size in the subject;
reducing hemorrhage score as assessed by intracerebral hemorrhage score in the subject;
reducing incidence of a hemorrhage in a subject;
reducing the likelihood of lethal hemorrhage in a subject;
reducing brain edema in the subject following stroke; and/or
reducing blood-brain-barrier breakdown or leakage in the subject following stroke.

### Claim 13 (depends on 1)

The method of claim 1, wherein the stroke is an ischemic stroke.

### Claim 14 (depends on 1)

The method of claim 1, wherein the compound that inhibits VEGF-B signaling binds to VEGF-B.

### Claim 15 (depends on 14)

The method of claim 14, wherein the compound is a protein comprising an antibody variable region that binds to or specifically binds to VEGF-B and neutralizes VEGF-B signaling.

### Claim 16 (depends on 15)

The method of claim 15, wherein the compound is a protein comprising a Fv.

### Claim 17 (depends on 16)

The method of claim 16, wherein the protein is selected from the group consisting of:
(i) a single chain Fv fragment (scFv);
(ii) a dimeric scFv (di-scFv); or
(iii) a diabody;
(iv) a triabody;
(v) a tetrabody;
(vi) a Fab;
(vii) a F(ab′)2;
(viii) a Fv;
(ix) one of (i) to (ix) linked to a constant region of an antibody, Fc or a heavy chain constant domain (CH) 2 and/or CH3; or
(x) an antibody.

### Claim 18 (depends on 17)

The method of claim 17, wherein the compound is:
(i) a protein comprising an antibody variable region that competitively inhibits the binding of antibody 2H10 (comprising a heavy chain variable region (VH) comprising a sequence set forth in SEQ ID NO: 2 and a light chain variable region (VL) comprising a sequence set forth in SEQ ID NO: 3) to VEGF-B; or
(ii) a protein comprising a humanized form of a variable region of antibody 2H10; or
(iii) a humanized form of antibody 2H10; or
(iv) an antibody comprising a VH comprising a sequence set forth in SEQ ID NO: 5 and a VL comprising a sequence set forth in SEQ ID NO: 6.

### Claim 19 (depends on 1)

The method of claim 1, wherein the compound that inhibits VEGF-B signaling inhibits or prevents expression of VEGF-B.

### Claim 20 (depends on 19)

The method of claim 19, wherein the compound is selected from the group an antisense, a siRNA, a RNAi, a ribozyme and a DNAzyme.
